The coronavirus infectious disease (COVID-19) shows a remarkable symptomatic
heterogeneity. Several risk factors including advanced age, previous illnesses, and a …

Persistent COVID-19 infection is a unique concern in patients with hematologic
malignancies. While vaccination against severe acute respiratory syndrome coronavirus 2 …

Patients with hematologic malignancies and recipients of hematopoietic cell transplantation
(HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have …

Background Patients with hematological malignancies (HM) are at high risk of mortality from
SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse …

The efficacy of SARS-CoV-2 vaccination in patients with hematological malignancies (HM)
appears limited due to disease and treatment-associated immune impairment. We …

Abstract Coronavirus disease-19 (COVID-19) vaccine response data for patients with
hematologic malignancy, who carry high risk for severe COVID-19 illness, are incomplete. In …

Background Patients with cancer are considered highly vulnerable to the recent coronavirus
disease 2019 (COVID‐19) pandemic. However, there are still few data on COVID‐19 …

Background Patients with hematologic malignancies have impaired humoral immunity
secondary to their malignancy and its treatment, placing them at risk of severe coronavirus …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread
worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS …

Abstract Coronavirus disease 2019 (COVID-19) is an illness resulting from severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in late 2019. Patients with …